Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 4/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 9/20 | 0.43 |
| ▸ | PIP4K2A | P48426 | 4/20 | 0.43 |
| ▸ | PIP4K2B | P78356 | 4/20 | 0.43 |
| ▸ | BTK | Q06187 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | BLK | P51451 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14706382 | 0.89 | EGFR (0.49) | FGFR2EGFRPIP4K2APIP4K2BBTK | |
| SCHEMBL14693528 | 0.84 | SRC (0.54) | FGFR2FGFR1KDRFLT1KCNH2 | |
| SCHEMBL14693527 | 0.84 | SRC (0.54) | FGFR2FGFR1KDRFLT1KCNH2 | |
| SCHEMBL14693472 | 0.84 | BTK (0.46) | FGFR2FGFR1KDREGFRBTK | |
| SCHEMBL14693470 | 0.84 | BTK (0.46) | FGFR2FGFR1KDREGFRBTK | |
| SCHEMBL14706377 | 0.82 | JAK2 (0.49) | FGFR2FGFR1EGFRBTKJAK2 | |
| SCHEMBL14706384 | 0.80 | FGFR2 (0.42) | FGFR2EGFRPIP4K2APIP4K2BBTK | |
| SCHEMBL14693477 | 0.80 | BTK (0.46) | FGFR2FGFR1KDRFLT1KCNH2 | |
| SCHEMBL14693480 | 0.80 | BTK (0.46) | FGFR2FGFR1KDRFLT1KCNH2 | |
| SCHEMBL14693422 | 0.77 | BTK (0.53) | FGFR2KDREGFRBTKLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9546172-B2 | Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2017-01-17 | — | — | US | disclosed |
| US-9546172-B2 | Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2017-01-17 | — | — | US | disclosed |
| US-9273051-B2 | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273051-B2 | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2016-03-01 | — | — | US | disclosed |
| US-20130172314-A1 | PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172314-A1 | PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| WO-2013102059-A1 | PYRAZOLO [3, 4-D] PYRIMIDINE AND PYRROLO [2, 3-D] PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| US-8377946-B1 | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377946-B1 | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172314-A1 | PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, LYN | FGFR2 983/4885FGFR1 1752/4885KDR 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.